Pervasive developmental disorder

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

Retrieved on: 
Monday, January 8, 2024

11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the United States Patent and Trademark Office (USPTO) for its patent application number 17/890,083.

Key Points: 
  • 11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the United States Patent and Trademark Office (USPTO) for its patent application number 17/890,083.
  • Anavex’s newest patent expands coverage of ANAVEX®2-73 (blarcamesine) therapy to ameliorate various conditions associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein (MeCP2).
  • This newest patent is expected to remain in force at least until January 2037, not including any patent term extension.
  • The grant of this new patent to Anavex further demonstrates our strong overall commitment to protecting the innovation and commercial opportunity of our product portfolio.”

Netsmart Partners with The Arc Erie County and The Arc of Monroe County to Enhance Care Coordination and Evidence-Based Care Programs

Retrieved on: 
Tuesday, December 14, 2021

The Arc Erie County and The Arc of Monroe County will use the comprehensive suite of solutions to seamlessly connect data from individual care plans and optimize documentation and clinical workflows to better serve their evidence-based care programs.

Key Points: 
  • The Arc Erie County and The Arc of Monroe County will use the comprehensive suite of solutions to seamlessly connect data from individual care plans and optimize documentation and clinical workflows to better serve their evidence-based care programs.
  • When the software does not move into the future with you, it limits the potential for the agency, said The Arc Erie County CEO Doug DiGesare.
  • The Netsmart CareFabric platform is designed to fully empower agencies committed to the four principles of person-centered care: dignity, coordinated care, personalized care and assisting an individual to live independently.
  • We couldnt be more thrilled to welcome two more Arc agencies to the Netsmart family, said Netsmart CEO Mike Valentine.

"One Red and One Green" Fruits and Vegetables Make a Distinctive and Prosperous Industry

Retrieved on: 
Wednesday, August 4, 2021

BAISE, China, Aug. 4, 2021 /PRNewswire/ -- Recently, the first China mango industry conference was held in Baise, Guangxi.

Key Points: 
  • BAISE, China, Aug. 4, 2021 /PRNewswire/ -- Recently, the first China mango industry conference was held in Baise, Guangxi.
  • Located in the west of Guangxi, Tianyang District of Baise is the first hometown of mango in China.
  • Given a subtropical monsoon climate with warm winter and long summer, and abundant sunshine, Tianyang is dubbed as "natural greenhouse" and is abundant in fruits and vegetables.
  • Relying on its exceptional climate, Tianyang District has made great efforts to develop the two dominant industries of mango and tomato.

"One Red and One Green" Fruits and Vegetables Make a Distinctive and Prosperous Industry

Retrieved on: 
Wednesday, August 4, 2021

BAISE, China, Aug. 4, 2021 /PRNewswire/ -- Recently, the first China mango industry conference was held in Baise, Guangxi.

Key Points: 
  • BAISE, China, Aug. 4, 2021 /PRNewswire/ -- Recently, the first China mango industry conference was held in Baise, Guangxi.
  • Located in the west of Guangxi, Tianyang District of Baise is the first hometown of mango in China.
  • Given a subtropical monsoon climate with warm winter and long summer, and abundant sunshine, Tianyang is dubbed as "natural greenhouse" and is abundant in fruits and vegetables.
  • Relying on its exceptional climate, Tianyang District has made great efforts to develop the two dominant industries of mango and tomato.

Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates

Retrieved on: 
Thursday, February 6, 2020

We announced January 8, 2020 that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No.

Key Points: 
  • We announced January 8, 2020 that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No.
  • 10,507,196 to support Anavexs leading drug candidate, ANAVEX2-73 (blarcamesine) for the treatment of neurodevelopmental disorders including Rett syndrome, and multiple sclerosis.
  • This patent is expected to remain in force at least until 2037, not including any patent term extensions.
  • On January 27, 2020, we announced that we have met our enrollment target for the ANAVEX2-73 (blarcamesine) Phase 2 study1 in Parkinsons Disease Dementia (PDD).